Intention-to-treat analysis for failure-free and overall survival by treatment and FLIPI risk group in the clinical study cohort. Failure-free survival (A) and overall survival (B) by randomization status in 431 patients receiving R-CHOP within the GLSG2000 trial. Failure-free survival (C) and overall survival (D) by randomization status and FLIPI risk group. The hazard ratio and P value given in panel C are derived from Cox regression.